We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Acal | LSE:ACL | London | Ordinary Share | GB0000055888 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 320.25 | 320.00 | 324.75 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Dec 2019 to Dec 2024
Nestle SA (NESN.VX) said Monday it sees no reason to renegotiate deal terms on eyecare company Alcon Inc. (ACL) with Swiss drugmaker Novartis AG (NVS).
"We firmly believe the business continues to deliver excellent results and therefore there is no need to renegotiate any contractual terms of the agreement," James Singh said at an investor event.
Singh is Nestle's head of finance and control.
Company Web site: www.nestle.com
-By Katharina Bart, Dow Jones Newswires; +41 43 443 8043; katharina.bart@dowjones.com
1 Year Acal Chart |
1 Month Acal Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
